Page 74 - Škrgat, Sabina, ed. 2023. Severe Asthma Forum - Monitoring and Treatable Traits in Severe Asthma. Koper: University of Primorska Press. Severe Asthma Forum, 2
P. 74
matory profile of exacerbations in pa- Practice. Chest. 2021 May;159(5):1734-
tients with severe refractory eosinophil- 46.
severe asthma forum 2: severe asthma - monitoring and treatable traits in severe asthma ic asthma receiving mepolizumab (the 39. Halling AS, Loft N, Silverberg JI, et al.
MEX study): a prospective observa- Real-world evidence of dupilumab ef-
tional study. Lancet Respir Med. 2021 ficacy and risk of adverse events: A sys-
Oct;9(10):1174-84. tematic review and meta-analysis. J Am
32. Matucci A, Nencini F, Vivarelli E, et Acad Dermatol. 2021 Jan;84(1):139-47.
al. Immunogenicity-unwanted immune 40. Fitzpatrick AM, Szefler SJ, Mauger DT,
responses to biological drugs – can we et al. Development and initial validation
predict them?, Exp Rev Clin Pharma- of the Asthma Severity Scoring Sys-
col. 2021 Jan;14(1):47-53. tem (ASSESS). J Allergy Clin Immunol.
33. Mukherjee M, Bulir DC, Radford K, 2020 Jan;145(1):127-39.
et al. Sputum autoantibodies in pa- 41. Schatz M, Kosinski M, Yarlas AS, et al.
tients with severe eosinophilic asth- The minimally important difference of
ma. J Allergy Clin Immunol. 2018 the asthma control test. J Allergy Clin
Apr;141(4):1269-79. Immunol. 2009 Oct;124(4):719-23.
34. Mukherjee M, Lim HF, Thomas S, et doi:10.1016/j.jaci.2009.06.053
al. Airway autoimmune responses in se- 42. Korn S, Both J, Jung M et al. Prospec-
vere eosinophilic asthma following low- tive evaluation of current asthma con-
dose Mepolizumab therapy. Allergy trol using ACQ and ACT compared
Asthma Clin Immunol. 2017 Jan 6:13:2. with GINA criteria. Ann Allergy Asth-
doi: 10.1186/s13223-016-0174-5. ma Immunol. 2011 Dec;107(6):474-9.
35. Rup B, Pallardy M, Sikkema D, et al. 43. Lanario JW, Burns L. Use of Health
Standardizing terms, definitions and Related Quality of Life in Clinical Tri-
concepts for describing and interpret- als for Severe Asthma: A Systemat-
ing unwanted immunogenicity of bi- ic Review. J Asthma Allergy. 2021 Aug
opharmaceuticals: recommendations 12:14:999-1010.
of the Innovative Medicines Initiative 44. Hossny, E., Caraballo, L., Casale, T.
ABIRISK consortium. Clin Exp Immu- et al. Severe asthma and quality of
nol. 2015 Sep;181(3):385-400. life. World Allergy Organ J. 2017 Aug
36. Busse WW, Bleecker ER, FitzGerald 21;10(1):28. doi: 10.1186/s40413-017-
JM, et al: BORA study investigators. 0159-y.
Long-term safety and efficacy of benral- 45. Price DB, Trudo F, Voorham J et al. Ad-
izumab in patients with severe, uncon- verse outcomes from initiation of sys-
trolled asthma: 1-year results from the temic corticosteroids for asthma: long-
BORA phase 3 extension trial. Lancet term observational study. J Asthma Al-
Respir Med. 2019 Jan;7(1):46-59. lergy. 2018 Aug 29:11:193-204. doi:
37. Korn S, Bourdin A, Chuupp G et al. In- 10.2147/JAA.S176026.
tegrated Safety and Efficacy Among pa- 46. Price D, Castro M, Bourdin A et al.
tients Receiving Benralizumab for Up Short-course systemic corticosteroids
5 Years. J Allerg Clin Immunol Pract. in asthma: striking the balance be-
2021 Dec;9(12):4381-92.e4. tween efficacy and safety. Eur Respir
38. Wechsler ME, Peters SP, Hill TD, et al. Rev. 2020 Apr 3;29 (155):190151. doi:
Clinical Outcomes and Health-Care 10.1183/16000617.0151-2019.
Resource Use Associated With Resli- 47. Loureiro CC, Ferreira MB, Ferreira J et
zumab Treatment in Adults With Se- al. Reducing oral corticosteroids in se-
vere Eosinophilic Asthma in Real-World vere asthma (ROSA Project): a nation-
tients with severe refractory eosinophil- 46.
severe asthma forum 2: severe asthma - monitoring and treatable traits in severe asthma ic asthma receiving mepolizumab (the 39. Halling AS, Loft N, Silverberg JI, et al.
MEX study): a prospective observa- Real-world evidence of dupilumab ef-
tional study. Lancet Respir Med. 2021 ficacy and risk of adverse events: A sys-
Oct;9(10):1174-84. tematic review and meta-analysis. J Am
32. Matucci A, Nencini F, Vivarelli E, et Acad Dermatol. 2021 Jan;84(1):139-47.
al. Immunogenicity-unwanted immune 40. Fitzpatrick AM, Szefler SJ, Mauger DT,
responses to biological drugs – can we et al. Development and initial validation
predict them?, Exp Rev Clin Pharma- of the Asthma Severity Scoring Sys-
col. 2021 Jan;14(1):47-53. tem (ASSESS). J Allergy Clin Immunol.
33. Mukherjee M, Bulir DC, Radford K, 2020 Jan;145(1):127-39.
et al. Sputum autoantibodies in pa- 41. Schatz M, Kosinski M, Yarlas AS, et al.
tients with severe eosinophilic asth- The minimally important difference of
ma. J Allergy Clin Immunol. 2018 the asthma control test. J Allergy Clin
Apr;141(4):1269-79. Immunol. 2009 Oct;124(4):719-23.
34. Mukherjee M, Lim HF, Thomas S, et doi:10.1016/j.jaci.2009.06.053
al. Airway autoimmune responses in se- 42. Korn S, Both J, Jung M et al. Prospec-
vere eosinophilic asthma following low- tive evaluation of current asthma con-
dose Mepolizumab therapy. Allergy trol using ACQ and ACT compared
Asthma Clin Immunol. 2017 Jan 6:13:2. with GINA criteria. Ann Allergy Asth-
doi: 10.1186/s13223-016-0174-5. ma Immunol. 2011 Dec;107(6):474-9.
35. Rup B, Pallardy M, Sikkema D, et al. 43. Lanario JW, Burns L. Use of Health
Standardizing terms, definitions and Related Quality of Life in Clinical Tri-
concepts for describing and interpret- als for Severe Asthma: A Systemat-
ing unwanted immunogenicity of bi- ic Review. J Asthma Allergy. 2021 Aug
opharmaceuticals: recommendations 12:14:999-1010.
of the Innovative Medicines Initiative 44. Hossny, E., Caraballo, L., Casale, T.
ABIRISK consortium. Clin Exp Immu- et al. Severe asthma and quality of
nol. 2015 Sep;181(3):385-400. life. World Allergy Organ J. 2017 Aug
36. Busse WW, Bleecker ER, FitzGerald 21;10(1):28. doi: 10.1186/s40413-017-
JM, et al: BORA study investigators. 0159-y.
Long-term safety and efficacy of benral- 45. Price DB, Trudo F, Voorham J et al. Ad-
izumab in patients with severe, uncon- verse outcomes from initiation of sys-
trolled asthma: 1-year results from the temic corticosteroids for asthma: long-
BORA phase 3 extension trial. Lancet term observational study. J Asthma Al-
Respir Med. 2019 Jan;7(1):46-59. lergy. 2018 Aug 29:11:193-204. doi:
37. Korn S, Bourdin A, Chuupp G et al. In- 10.2147/JAA.S176026.
tegrated Safety and Efficacy Among pa- 46. Price D, Castro M, Bourdin A et al.
tients Receiving Benralizumab for Up Short-course systemic corticosteroids
5 Years. J Allerg Clin Immunol Pract. in asthma: striking the balance be-
2021 Dec;9(12):4381-92.e4. tween efficacy and safety. Eur Respir
38. Wechsler ME, Peters SP, Hill TD, et al. Rev. 2020 Apr 3;29 (155):190151. doi:
Clinical Outcomes and Health-Care 10.1183/16000617.0151-2019.
Resource Use Associated With Resli- 47. Loureiro CC, Ferreira MB, Ferreira J et
zumab Treatment in Adults With Se- al. Reducing oral corticosteroids in se-
vere Eosinophilic Asthma in Real-World vere asthma (ROSA Project): a nation-
